177Lutetium octreotate therapy
177Lutetium octreotate therapy can be used to treat neuroendocrine tumours (NETs). This treatment is suitable for patients where treatment, such as surgery or chemotherapy, aren’t suitable or haven’t proved successful.
What is 177Lutetium octreotate therapy
Why would I be offered 177Lutetium octreotate therapy?
You may be offered 177Lutetium octreotate therapy if you have tumours that start in your endocrine or nervous system. These are known as neuroendocrine tumours (NETs). It is used when other types of treatment, such as surgery or chemotherapy, aren’t suitable or haven’t worked.
This therapy helps to:
- Stop the NETs from growing
- Reduce the size of the tumour
- Improve your symptoms
In some cases, NETs reduce in size for a long period of time, giving long-term remission from the disease, but this therapy can’t cure your cancer.
Before you start treatment, you’ll have a diagnostic PET/CT scan.
The scan helps us to see whether the cancer has somatostatin receptors. It identifies the location of the cancer so that it can be precisely targeted and helps in staging and planning your treatment.
177Lutetium octreotate therapy is an outpatient procedure in our Theranostics suite. Your treatment will be delivered over four hours by a drip inserted into a vein in your arm.
Most people have four treatment carried out at 4-8 week intervals between treatments. Your therapy will be personalised according to your response and symptoms.
177Lutetium is cleared from your body when you urinate, with 60% eliminated within 24 hours of treatment.
Like all cancer treatments, there can be side-effects. They vary from person to person, but may include:
- A temporary increase in your cancer symptoms
We’ll help you find ways to reduce and manage any side-effects. You may be able to have medication to reduce any symptoms.
Make an enquiry about 177Lutetium octreotate therapy
How to find us
Meet Dr Yong Du
Dr Yong Du
MBBS MSc PhD FRCP
Dr Yong Du is a Consultant Physician in Nuclear Medicine & PET/CT. He has extensive experience in both Diagnostic and Therapeutic Nuclear Medicine and was the first recipient of the UK HEFCE Clinical Senior Lectureship award in the Nuclear Medicine specialty.